## PMT3-B-2 — SUBJECT VISIT PLAN RECORD

#### **Inclusion Criteria**

Patients with definite pheochromocytoma or paraganglioma (PPGLs)

Male and female patients (all ages, including children above 5 years) with definite diagnosed PPGLs are included on the basis of the following:

Patients with definite diagnosed PPGLs.

- (i) based on histological examination of resected or biopsied tumor material.
- (ii) when tumor material is not available for histological examination, (i.e., patients with metastatic disease) inclusion may be based on imaging evidence of metastatic disease (including functional imaging evidence) combined with either a past history of a pathologically proven PPGL or biochemical evidence of excess catecholamine production definitive for a PPGL.


#### **Exclusion Criteria**

- (i) Subjects with impaired mental capacity that precludes informed consent.
- Subjects who require medications that would interfere with or invalidate primary outcome parameters (e.g., tricyclic antidepressants).

G. Eisenhofer <u>26/7/13</u>2<del>5/7/13</del> PMT3 STUDY

### Flow chart for patients with definite PPGLs

(the numbers of patients expected to participate through study)



Inclusion: three years Follow time: open

**Comment [NQ1]:** Also refer the flowchart for A1 in powerpoint file.

G. Eisenhofer 26/7/1325/7/13 PMT3 STUDY

РМТ3					
1. Last Name:	2. First Name:				
3. Gender:	4. DOB:				
5. Address:					
6. Tel (home):	7. Mobile:				
8. Next of kin:					
A: Last Name:	B: First Name:				
C: Address:					
F: Tel (home):	G: Mobile:				
Referring or Personal Physician:					
10. Study Center:					
11. Date: H&P Performed:					
12. Date: consent obtained:					
Therapy resistant hypertens Incidental finding on imaging Routine screening due to kn					

Unique patient identifier and Date Consent signed

Affix HEP MET/CAT Record Label with date of sample

Other: \_\_\_

Affix EDTA DNA Record Label with date of sample Affix URIN 24 Record Label with date of sample

G. Eisenhofer <u>26/7/13</u>25<del>/7/13</del> PMT3 STUDY

# Specific questions:

Medical History												
	Patient has history of previous PPGL											
	Date diagnosed		tumor	Tumor location		Dimensions (c			m)			
	Year	Month	resected	A or	or E Details		X	у	Z			
1												
3												
4												
5												
	Patient ha	as residua	l disease		R	esidual d	disease	e is m	etastati	c		
					If YES, locations and No. of lesions							
1					В	ones	Lymp		Lungs		Liver	
╛_												
J _	Detient he		<u> </u>									
	Patient ha			disease		Diagno		me	edicatio	n	dose/da	V
	ii 120, ac	tan what		uiscasc		ycc		IIIC	Jaioatio		dosc/da	.y
I												_
												-

G. Eisenhofer <u>26/7/13</u>25<del>/7/13</del> PMT3 STUDY

Нє	ereditary PPGL syndrome
	Patient has evidence of hereditary syndrome y/n
	Evidence includes family history of PPGL's y/n
	Indicate number of 1e degree relatives with PPGL's
	Indicate number of 2e defree relatives with PPGL's
	Evidence includes clinical stigmata y/n
	if YES, detail
	Indicate syndrome
	Specific details
	Specific aggected gene(s)

G. Eisenhofer <u>26/7/13</u>25<del>/7/13</del> PMT3 STUDY